Safety warnings issued for biotechnology derived pharmaceuticals approved since 1995

被引：0
|
作者：
Giezen, T. J. [1 ,5 ]
Mantel-Teeuwisse, A. K. [1 ,2 ]
Straus, S. M. J. [2 ]
Schellekens, H. [4 ,5 ]
Egberts, A. C. G. [1 ,3 ]
Leufkens, H. G. M. [1 ]
机构：
[1] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[2] Med Evaluat Board, The Hague, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands
[4] Univ Utrecht, Dept Innovat Sci, Utrecht, Netherlands
[5] Utrecht Inst Pharmaceut Sci, Div Pharmaceut, Utrecht, Netherlands
来源：
DRUG SAFETY | 2007年 / 30卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：968 / 968
页数：1
相关论文
共 50 条
  • [1] Safety warnings issued
    不详
    [J]. BIOPHARM INTERNATIONAL, 2006, 19 (02) : 14 - 14
  • [2] Preclinical safety evaluation of biotechnology-derived pharmaceuticals
    Joy A. Cavagnaro
    [J]. Nature Reviews Drug Discovery, 2002, 1 : 469 - 475
  • [3] Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond
    Serabian, MA
    Pilaro, AM
    [J]. TOXICOLOGIC PATHOLOGY, 1999, 27 (01) : 27 - 31
  • [4] Outlook - Preclinical safety evaluation of biotechnology-derived pharmaceuticals
    Cavagnaro, JA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (06) : 469 - 475
  • [5] Safety related regulatory actions for biologicals approved in the US and Europe since 1995
    Giezen, Thijs J.
    Mantel-Teeuwisse, Aukje K.
    Straus, Sabine M.
    Schellekens, Huub
    Leufkens, Hubert G.
    Egberts, Antoine C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S29 - S30
  • [6] Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations
    Vahle, John L.
    Finch, Gregory L.
    Heidel, Shawn M.
    Hovland, David N., Jr.
    Ivens, Inge
    Parker, Suezanne
    Ponce, Rafael A.
    Sachs, Clifford
    Steigerwalt, Ronald
    Short, Brian
    Todd, Marque D.
    [J]. TOXICOLOGIC PATHOLOGY, 2010, 38 (04) : 522 - 553
  • [7] The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals
    Pilling, AM
    [J]. TOXICOLOGIC PATHOLOGY, 1999, 27 (06) : 678 - 688
  • [8] Preclinical safety testing of biotechnology-derived pharmaceuticals - Understanding the issues and addressing the challenges
    Brennan, FR
    Shaw, L
    Wing, MG
    Robinson, C
    [J]. MOLECULAR BIOTECHNOLOGY, 2004, 27 (01) : 59 - 74
  • [9] Pharmaceuticals produced by biotechnology: Quality and safety issues
    Dayan-Kenigsberg, J
    [J]. ANIMAL CELL TECHNOLOGY: FROM TARGET TO MARKET, 2001, 1 : 471 - 476
  • [10] Preclinical safety evaluation of biotechnology-derived pharmaceuticals: ICH step 4 harmonised tripartite guideline
    [J]. SAFETY EVALUATION OF BIOTECHNOLOGICALLY-DERIVED PHARMACEUTICALS: FACILITATING A SCIENTIFIC APPROACH, 1998, : 169 - 187
12345